This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1a8j

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="1a8j" size="450" color="white" frame="true" align="right" spinBox="true" caption="1a8j, resolution 2.7&Aring;" /> '''IMMUNOGLOBULIN LAMBDA...)
Current revision (15:22, 13 March 2024) (edit) (undo)
 
(16 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:1a8j.gif|left|200px]]<br /><applet load="1a8j" size="450" color="white" frame="true" align="right" spinBox="true"
 
-
caption="1a8j, resolution 2.7&Aring;" />
 
-
'''IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME'''<br />
 
-
==Overview==
+
==IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME==
-
OBJECTIVE: The binding of sweet-tasting compounds in a human (Mcg), Bence-Jones dimer has been characterized by x-ray crystallography., Aspartame binding in this immunoglobulin fragment is remarkable., Unexpected pain relief noted by A.B.E., a crystallographer with diagnosed, osteoarthritis, suggested that the accommodation of aspartame in the, active site of the dimer may represent surrogate binding by other, proteins, with analgesia as the outcome. METHODS: X-ray analysis of the, complex of aspartame and the Bence-Jones dimer was conducted with, crystalline Mcg protein and pure aspartame. A single-blind (n = 1) study, to confirm analgesia was completed by administration of aspartame to, A.B.E. A controlled double-blind trial was performed in patients with, x-ray-documented osteoarthritis. Pain and performance changes were, evaluated with use of two doses of placebo and two doses of aspartame., Effects on bleeding time were then evaluated by determination of template, bleeding times in 34 normal volunteers. Finally, antipyretic effects were, studied in Sprague-Dawley rats given intramuscular turpentine injections., RESULTS: Aspartame binding in the Bence-Jones dimer was verified by x-ray, crystallography. Improvements in performance and pain relief were observed, in A.B.E. at p &lt; 0.001. Decreased pain and improved performance were also, observed in patients with osteoarthritis (p &lt; 0.001). Mild antihemostatic, responses were observed in bleeding times after aspartame treatment., Modified template bleeding times increased at p &lt; 0.01. Aspartame blocked, the turpentine-mediated febrile responses in the treated rats (p &lt; 0.01)., CONCLUSIONS: L-Aspartyl-L-phenylalanine methyl ester is biologically, active and appears to relieve pain, induce mild antithrombotic effects in, humans, and decrease fever in animals.
+
<StructureSection load='1a8j' size='340' side='right'caption='[[1a8j]], [[Resolution|resolution]] 2.70&Aring;' scene=''>
-
 
+
== Structural highlights ==
-
==About this Structure==
+
<table><tr><td colspan='2'>[[1a8j]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1A8J OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1A8J FirstGlance]. <br>
-
1A8J is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PME as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1A8J OCA].
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.7&#8491;</td></tr>
-
 
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene>, <scene name='pdbligand=PME:N-L-ALPHA-ASPARTYL+L-PHENYLALANINE+1-METHYL+ESTER'>PME</scene></td></tr>
-
==Reference==
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1a8j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1a8j OCA], [https://pdbe.org/1a8j PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1a8j RCSB], [https://www.ebi.ac.uk/pdbsum/1a8j PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1a8j ProSAT]</span></td></tr>
-
Treatment of osteoarthritis with aspartame., Edmundson AB, Manion CV, Clin Pharmacol Ther. 1998 May;63(5):580-93. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=9630831 9630831]
+
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/LV208_HUMAN LV208_HUMAN] V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref> <ref>PMID:24600447</ref>
 +
== Evolutionary Conservation ==
 +
[[Image:Consurf_key_small.gif|200px|right]]
 +
Check<jmol>
 +
<jmolCheckbox>
 +
<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/a8/1a8j_consurf.spt"</scriptWhenChecked>
 +
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
 +
<text>to colour the structure by Evolutionary Conservation</text>
 +
</jmolCheckbox>
 +
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1a8j ConSurf].
 +
<div style="clear:both"></div>
 +
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
-
[[Category: Single protein]]
+
[[Category: Large Structures]]
-
[[Category: Edmundson, A.B.]]
+
[[Category: Edmundson AB]]
-
[[Category: Manion, C.V.]]
+
[[Category: Manion CV]]
-
[[Category: PME]]
+
-
[[Category: aspartame]]
+
-
[[Category: immunoglobulin]]
+
-
[[Category: immunotherapeutic agent]]
+
-
[[Category: ligand binding]]
+
-
[[Category: mcg(human) bence-jones dimer]]
+
-
[[Category: surrogate receptor]]
+
-
 
+
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Nov 20 10:40:55 2007''
+

Current revision

IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME

PDB ID 1a8j

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1a8j"
Personal tools